GlobeNewswire

Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO

GlobeNewswire

BASEL, Switzerland – October 19, 2026 – Nouscom, a clinical-stage, cancer interception focused biotech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing. The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures), and Neva SGR (Intesa Sanpaolo Group). Nouscom’s other existing international life sciences investors, 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance (through its InnoBio2 fund), CDP Venture Capital (through its Large Ventures Fund), EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures, all participated in the round. The strong demand for the round reflects investor conviction in Nouscom’s pipeline and recently published clinical data.